Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 808

Results For "ENT"

9347 News Found

Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval
Biotech | February 01, 2022

Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval

Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel


Alembic receives USFDA approval for clarithromycin tablets
Drug Approval | February 01, 2022

Alembic receives USFDA approval for clarithromycin tablets

Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA


DRiefcase app for Ayushman Bharat Digital Mission
Digitisation | January 31, 2022

DRiefcase app for Ayushman Bharat Digital Mission

ABDM is a digital framework that will connect patients, doctors and other healthcare stakeholders nationwide to facilitate safe and secure movement of health information


Pharma industry seeks fiscal support to drive innovation
News | January 31, 2022

Pharma industry seeks fiscal support to drive innovation

Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India


Daiichi Sankyo commences trial for booster mRNA vaccine against Covid-19
Biotech | January 31, 2022

Daiichi Sankyo commences trial for booster mRNA vaccine against Covid-19

DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company


Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
News | January 31, 2022

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

ICICI Direct analysis of Dr Reddy’s Q3FY22 results


Granules Pharmaceuticals concludes USFDA audit with three minor observations
News | January 31, 2022

Granules Pharmaceuticals concludes USFDA audit with three minor observations

The audit is a PAI for two of its product applications filed from this facility


Cipla has strong traction in India and the US: ICICI Direct
News | January 31, 2022

Cipla has strong traction in India and the US: ICICI Direct

ICICI Direct’s analysis of Cipla’s Q3FY22 results


Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.
News | January 31, 2022

Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.

Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021


ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct
News | January 29, 2022

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct